Recent Updates
Recently added Catalysts

procarbazine

Phase 3

Brain and Central Nervous System Tumors | Small molecule | Oncology |Pfizer, Inc.|Last Updated: Sep 11, 2012

Target and mechanism

ModalitySmall molecule

Also known as procarbazine hydrochloride

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials1
Total Enrollment -

FDA Designations

No designations recorded

Clinical trial landscape

procarbazine · 1 trial · 1 indication

Phase 3 1
NCT00003293SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma MultiformeBrain and Central Nervous System Tumors
COMPLETED- Analytics
PHASE3COMPLETED
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
Brain and Central Nervous System Tumors
NCT00003293-
Unlock trial analytics

Study Design & Arms

AllocationRANDOMIZED
PurposeTREATMENT

Interventions

NameTypeDescription
leflunomideDRUG -
procarbazine hydrochlorideDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites35

DISEASE CHARACTERISTICS: Histologically proven refractory or recurrent supratentorial glioblastoma multiforme Bidimensionally measurable, enhancing residual disease by T1-weighted gadolinium-enhanced MRI required within 15 days prior to treatment Stable dose of corticosteroids required for at least ...

Countries:United StatesCanada
Unlock Eligibility Criteria